Top > Search of International Patents > ANTIGEN-AND-DRUG VEHICLE COMPRISING SYNTHETIC PEPTIDE, AND MUCOSAL VACCINE USING THE SAME

ANTIGEN-AND-DRUG VEHICLE COMPRISING SYNTHETIC PEPTIDE, AND MUCOSAL VACCINE USING THE SAME achieved

Foreign code F110002753
File No. S2008-0401-C0
Posted date Apr 13, 2011
Country WIPO
International application number 2009JP056508
International publication number WO 2009123119
Date of international filing Mar 30, 2009
Date of international publication Oct 8, 2009
Priority data
  • P2008-096244 (Apr 2, 2008) JP
Title ANTIGEN-AND-DRUG VEHICLE COMPRISING SYNTHETIC PEPTIDE, AND MUCOSAL VACCINE USING THE SAME achieved
Abstract Disclosed are: an antigen-and-drug (AD) vehicle utilizing a novel synthetic peptide; and a mucosal vaccine. Specifically disclosed are: an antigen-and-drug (AD) vehicle comprising a complex of a lipid and a synthetic peptide which can induce the production of a secreted IgA antibody and comprises the amino acid sequence PVHLKRLm [wherein m represents a number of 11 to 15 or 16-20; e.g., the peptide depicted in SEQ ID NO:1] or KnLm [wherein n represents a number of 4 to 8 and m represents a number of 11 to 20; e.g., the peptide depicted in SEQ ID NO:2 or SEQ ID NO:3]; and a mucosal vaccine produced by allowing such an amount of an antigen that a mucosal immunity IgA can be induced to coexist with the AD vehicle, by contacting the above-mentioned amount of an antigen with the AD vehicle, by capturing above-mentioned amount of an antigen by the AD vehicle, or by adsorbing the above-mentioned amount of an antigen on the AD vehicle.
Outline of related art and contending technology BACKGROUND ART
Patent Document 1 and 2 is, like the conventional inactivated vaccines or the disadvantages of the toxoid, such as immune adjuvants and mucosal vaccine development of current has been described in detail.
These Patent Documents 1, as described in 2, such as conventional intramuscular subcutaneously inoculated into from a vaccine, is the root of a natural infection of the virus to induce the production of the antibody IgA mucosa of switching to the mucosal vaccine need, wider and deeper recognized. In particular, as the next generation vaccine 21 st century, the production of antibodies IgA, inducing an immune response or mucosal local immune, so-called mucosal vaccine development and practical use is possible for the deficiencies of all over the world, has not been achieved yet.
The present inventors to solve this problem, the surfactant and the surfactant and/or pulmonary lung C B, lipid antigen in a complex with a drug (AD) and the vehicle, the vehicle AD mucosal vaccine from the antigen, and filed a patent application (Patent Document 1) are. Further the present inventors have found, and the amount of the antigen (V) vehicle AD (A) the amount of the weight ratio of V/A by adjusting the size, the specific production and selection of antibodies IgA IgA, both IgG antibody production and found that can be converted to, the mechanism of action of this mucosal vaccine and filed a patent (patent document 2). These patents Document 1, is 2, a fragment of a lung surfactant C B and the validity of the (peptide) is disclosed.
It should be noted that, as a synthetic peptide is associated with lung surfactant, which is to be made Patent Document 3-8.
Scope of claims (In Japanese)請求の範囲 [1]
以下のアミノ酸配列からなる合成ペプチド:
PVHLKRLm(ただしmは11-15または16-20);または
KnLm(ただしnは4-8、mは11-20)
と脂質との複合体である抗原薬物(AD)ビークル。

[2]
合成ペプチドが、配列番号1から3のいずれかのアミノ酸配列からなる請求項1の抗原薬物(AD)ビークル。

[3]
脂質が、ホスファチジルコリン、ジパルミトイルホスファチジルコリン、ホスファチジルセリン、ホスファチジルグリセロール、ホスファチジルイノシトール、ホスファチジルエタノールアミン、ホスファチジン酸、ラウリル酸、ミリスチン酸、パルミチン酸、ステアリン酸およびオレイン酸の少なくとも1種である請求項1の抗原薬物(AD)ビークル。

[4]
脂質が、ジパルミトイルホスファチジルコリン、ホスファチジルグリセロールおよびパルミチン酸の3種脂質混合物である請求項3の抗原薬物(AD)ビークル。

[5]
請求項1から4のいずれかに記載の抗原薬物(AD)ビークルに、粘膜免疫IgAを誘導する量の抗原を共存、接触、捕捉又は吸着させることにより得られる粘膜ワクチン。

[6]
抗原が伝染病病原体に由来の不活化抗原又は無毒化毒素である請求項5の粘膜ワクチン。

[7]
請求項1から4のいずれかに記載の抗原薬物(AD)ビークルに、アレルゲン、アレルゲンエピトープ、又はアレルゲン由来抗原を共存、接触、捕捉又は吸着させることにより得られるアレルギー予防剤又は治療剤。

[8]
請求項5に記載の粘膜ワクチンを、少なくとも2回投与することを特徴とする感染症の予防又は治療方法。

[9]
請求項7に記載のアレルギー予防又は治療剤を、少なくとも2回投与することを特徴とするアレルギーの予防又は治療方法。






  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • TOKUSHIMA UNIVERSITY
  • Inventor
  • KIDO, Hiroshi
  • TAKEI, Tsunetomo
  • MIZUNO, Dai
IPC(International Patent Classification)
Specified countries National States: AE AG AL AM AO AT AU AZ BA BB BG BH BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PG PH PL PT RO RS RU SC SD SE SG SK SL SM ST SV SY TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ MD RU TJ TM
EPO: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
Please contact us by E-mail or facsimile if you have any interests on this patent.

PAGE TOP

close
close
close
close
close
close